戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 iple myeloma treated within the context of a large clinical trial.
2 MM showing significant clinical benefit in a large clinical trial.
3 o reduce heart failure mortality in a recent large clinical trial.
4 reast cancer masses found on mammograms in a large clinical trial.
5  predicts antidepressant outcomes within two large clinical trials.
6  only modifiable risk factor demonstrated by large clinical trials.
7 e effectiveness of each line of therapy from large clinical trials.
8 injury, and sepsis, has not shown benefit in large clinical trials.
9 abetic macular edema (DME) using data from 2 large clinical trials.
10 95) or aspirin and clopidogrel (n=1110) in 2 large clinical trials.
11 one intravitreal implant (DEX) has varied in large clinical trials.
12 oducible method is needed for application to large clinical trials.
13 d potentially reduce the frequency of failed large clinical trials.
14 he performance of haemorrhage descriptors in large clinical trials.
15 ll-cause mortality compared with warfarin in large clinical trials.
16  diabetic macular edema has been proven with large clinical trials.
17 , but such a strategy has not been tested in large clinical trials.
18 ons that are currently being investigated in large clinical trials.
19 ent CETP inhibitors, are now being tested in large clinical trials.
20 gh this suggestion has not been validated in large clinical trials.
21 efficacy against severe rotavirus disease in large clinical trials.
22  adhesion and increased patient mortality in large clinical trials.
23 ssociated with outcome within the context of large clinical trials.
24 fects, are being tested (or soon will be) in large clinical trials.
25 e of these mutations has not been defined in large clinical trials.
26 ed in patients treated with ezetimibe in two large clinical trials.
27 ng polyps varies widely in recently reported large clinical trials.
28 hniques are currently under investigation in large clinical trials.
29  late ARDS support the need for confirmatory large clinical trials.
30 t the benefit of multiple recently published large clinical trials.
31 73 [60.8%] men, 47 [39.2%] women) from three large clinical trials (AFFECTS, P3, REFINE) who underwen
32 ent of the CHD risk associated with sdLDL in large clinical trials and has demonstrated convincingly
33 ine ligand 10 have recently been assessed in large clinical trials and hold promising potential for e
34 al Health and Nutrition Examination Surveys, large clinical trials and meta-analyses for statin benef
35                                              Large clinical trials and observational studies should c
36 ntagonists, have been investigated in recent large clinical trials and show significant promise both
37                                   Finally, 2 large clinical trials are formally putting the inflammat
38                                      Further large clinical trials are in place to enable the clinica
39                                              Large clinical trials are now planned to confirm or refu
40 rate the research process, particularly when large clinical trials are required.
41 ride-lowering therapies remains uncertain, 2 large clinical trials are testing the influence of omega
42                                              Large clinical trials are the criterion standard for mak
43        Recent, highly publicized failures of large clinical trials called into question the rigor, de
44 aluating their performance, where conducting large clinical trials can be expensive.
45                                         In a large clinical trial cohort of patients with IPF (n = 1,
46 tter (AFL) compared with chlorthalidone in a large clinical trial cohort with extended post-trial sur
47 lear whether this association is observed in large clinical trial cohorts with a high burden of exist
48 to investigate their prognostic value in two large clinical trial cohorts.
49 studies have not translated into benefits in large clinical trials conducted in the modern treatment
50                          Results from recent large clinical trials confirm that blunting of the renin
51                          However, additional large clinical trial data are required to more definitiv
52 ation of MS disease evolution by analyzing a large clinical trial database (approximately 8,000 patie
53 ioverter-defibrillators (ICDs) after several large clinical trials demonstrated their ability to effe
54                      When the results of two large clinical trials, ESPRIT and SILCAAT, showed no cli
55                                              Large clinical trials established the benefits of sodium
56                                            A large clinical trial evaluating the impact of IL-1beta i
57 lly to reduce new cases of colon cancer in 2 large clinical trials evaluating coronary events, althou
58                           In fact, all three large clinical trials failed to confirm estrogen's expec
59 ely, as guanfacine is currently the focus of large clinical trials for the treatment of delirium, and
60                                   Therefore, large clinical trials for these putative memory-enhancin
61                               In contrast, a large clinical trial found that intranasal esketamine at
62                                           No large clinical trials have addressed the role of antioxi
63                       In the past few years, large clinical trials have been conducted to assess the
64                                     Although large clinical trials have been formed to use this thera
65 , and patient satisfaction, data from recent large clinical trials have called the safety of this tec
66                                              Large clinical trials have clearly demonstrated morbidit
67                                          Two large clinical trials have demonstrated that fixed-dose
68 effects on thrombotic processes in vivo, but large clinical trials have failed to show benefits of 5-
69                        The results of recent large clinical trials have modified treatment plans form
70                                          Two large clinical trials have shown a reduced rate of breas
71                  Secondary outcomes in these large clinical trials have shown that VEGF inhibition im
72 reliable biomarker of COVID-19 severity, and large clinical trials have shown the potential for impro
73                                       Recent large clinical trials have supported the use of radiatio
74 ere measured before and after treatment in a large clinical trial in AAV: 163 subjects enrolled in th
75                                            A large clinical trial in coronary heart disease patients
76                                  Data from a large clinical trial in predominantly white US women (19
77 f individual patients, as well as to analyze large clinical trials in CML.
78                              Despite several large clinical trials in lupus nephritis, no second line
79    We summarize the results of the available large clinical trials in our understanding of the manage
80 etrapib and torcetrapib, have been tested in large clinical trials in statin-treated coronary heart d
81 d in the conduct and reporting of results of large clinical trials in these functional disorders are
82 ring LABA therapy and should be evaluated in large clinical trials including the current FDA-mandated
83 everal LMWH agents that have been studied in large clinical trials, including enoxaparin, dalteparin,
84                           Recently published large clinical trials, including the long-term results f
85                                 Although two large clinical trials investigating the fat/breast cance
86                                       In two large clinical trials, investigators found a potential r
87                        The experience from 2 large clinical trials involving the oral intake of 2000
88                                  A long-term large clinical trial is necessary to investigate the ben
89                                  A long-term large clinical trial is necessary to investigate the saf
90 iers outlined herein before the next wave of large clinical trials is under way.
91 tively unimpaired populations and could make large clinical trials more feasible and cost-effective.
92 diatric asthma clusters by using a separate, large clinical trials network.
93 sis was conducted among participants in this large clinical trial of calcium supplementation to preve
94                                            A large clinical trial of these naturally occurring substa
95 Based on a secondary analysis of data from a large clinical trial of trimethoprim-sulfamethoxazole pr
96                           As demonstrated in large clinical trials of 2 to 4 years' duration, these m
97 rocess and outcomes are compared between two large clinical trials of LDL cholesterol reduction with
98                                  Data from 2 large clinical trials of peginterferon and ribavirin wer
99                               Few long-term, large clinical trials of soy as a means of improving bon
100                                              Large clinical trials of such agents in patients with hi
101 ty from breast cancer chemotherapy, and even large clinical trials often do not report this informati
102                                          Two large clinical trials, one open-label (Stroke Prevention
103                       There are currently no large clinical trials or meta-analyses focusing on the t
104 ording to prospectively recorded data from a large clinical trial, patients whose colon cancer was re
105 ble, recent review articles and results from large clinical trials, preferably with outcomes from man
106 mulation, and disturbing safety signals in a large clinical trial prompted the Clinical Laboratory an
107                                      Several large clinical trials provide additional evidence indica
108                                        Three large clinical trials provoked major debate when hormone
109 en (Arg506Gln; FV Leiden), was examined in a large clinical trial (PROWESS) of severe sepsis and a mo
110  therapy (HRT) effects, and the first of the large clinical trials published its results during the p
111 e Hypertension Prevention Trial, three other large clinical trials reported differing effects of sodi
112                                       Recent large clinical trials show lower rates of late cardiovas
113                                            A large clinical trial showed short and long-term efficacy
114                                          Two large clinical trials showed marked reduction in acute c
115 be critical to include elderly asthmatics in large clinical trials so that therapy may be better tail
116 y responsiveness) of asthmatic children in a large clinical trial spanning 4 years.
117                                   Although 2 large clinical trials suggest a neutral effect on cardio
118 ted in clinical trials, subgroup analysis of large clinical trials suggests they may be less likely t
119                             The aggregate of large clinical trials supports the notion that statins m
120 redictors of remission and side effects in a large clinical trial that also incorporated cognitive as
121 ent cases and controls were derived from two large clinical trials that compared thalidomide with con
122                               Drawing from 5 large clinical trials that included all-trans retinoic a
123 ased on the results of three groundbreaking, large, clinical trials that demonstrated a significantly
124  this participant-level pooled analysis of 3 large clinical trials, the authors evaluated the effect
125 e publication of mature results from various large clinical trials, the European Association of Neuro
126 s been the subject of two recently completed large clinical trials, the Ocular Hypertension Treatment
127                                         In a large clinical trial, this new drug was found to reduce
128 tilises circulating tumour DNA analysis in a large clinical trial to demonstrate the subclonal divers
129                      We examined data from a large clinical trial to determine if chemotherapy dosing
130            We examined follow-up data from a large clinical trial to prospectively investigate the lo
131 ll-cell lung cancer who were randomized in a large clinical trial to receive intensive doxorubicin, c
132 se to calcimimetic agents, we used data from large clinical trials to analyze the effects of etelcalc
133                                              Large clinical trials to test novel strategies and pharm
134          Recent findings include several new large clinical trials, using both gene and protein thera
135  Although no deaths occurred in the original large clinical trial, we analyzed 10 serious adverse eve
136                   Using baseline data from a large clinical trial, we tested the discriminant validit
137 spite much basic research and many small and large clinical trials, we still do not know how angioten
138 g cancer death submodel in participants of a large clinical trial who ever smoked (n = 39 180) and th
139 rom mechanistic studies and clinical trials, large clinical trials with SGLT2 inhibitors are now inve
140  prescribed based on the average outcomes of large clinical trials, with limited personalization and

 
Page Top